Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[68Ga]Ga-TacBOMB2
- Development stage
- Preclinical
- Lead developer
- BC Cancer
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
[68Ga]Ga-TacBOMB2 is a gallium-68 labeled, gastrin-releasing peptide receptor (GRPR) agonist radiopharmaceutical developed by BC Cancer and the University of British Columbia. It is designed as a positron emission tomography (PET) imaging tracer for the detection of GRPR-expressing solid tumors, such as prostate and breast cancers. Chemically, it consists of a DOTA chelator conjugated via a 4-amino-1-carboxymethylpiperidine (Pip) linker to a modified bombesin analogue, [Thz14]Bombesin(7-14), where the C-terminal methionine is replaced with thiazoline-4-carboxylic acid (Thz). This modification retains high GRPR binding affinity and agonist properties while significantly reducing pancreatic uptake compared to other GRPR-targeting tracers, thereby improving the tumor-to-background contrast ratio and reducing potential radiotoxicity.
- Other names
- 68Ga-TacBOMB2[68Ga]Ga-DOTA-Pip-[D-Phe6,Thz14]Bombesin(6-14)[68Ga]Ga-DOTA-Pip-D-Phe6-Gln7-Trp8-Ala9-Val10-Gly11-His12-Leu13-Thz14-NH2
02
Targets
GRPR (Gastrin-releasing peptide receptor)
Beyond the preview
Go deeper on [68Ga]Ga-TacBOMB2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [68Ga]Ga-TacBOMB2.